Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

NIH

Sponsor class

Conditions

Advanced Melanoma
Recurrent Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Talimogene Laherparepvec

Sponsor

National Cancer Institute (NCI)